Agile Therapeutics provided an update on Twirla for 2022 and its commercial plan for 2023. 2022 Twirla Factory Sales: Twirla factory sales for the fourth quarter 2022 are expected to be approximately 42,200 total cycles, a 30% increase from the 33,282 total cycles reported for the third quarter 2022. The approximately 42,600 total cycles would represent an all-time high for single-quarter factory sales. Twirla factory sales for the full year 2022 are expected to be approximately 113,600 total cycles, a 232% increase from the 34,227 total cycles reported for the full year 2021. "Our first commercial product, Twirla, demonstrated accelerated growth in the second half of 2022 and now we are excited to enter 2023 with strong growth momentum," said Agile Therapeutics’ Chairman and Chief Executive Officer Al Altomari. "We expect to see that trend continue throughout 2023, even as we plan to hold our operating expenses at levels similar to the second half of 2022."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AGRX:
